TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05643690

Intervention type: DIAGNOSTIC_TEST
Intervention: UriFind Bladder Cancer Assay
Description: The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
Study: NCT06434064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO
Study: NCT05104723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELJANZ (tofacitinib)
Description: The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
Study: NCT06415058

Intervention type: DEVICE
Intervention: HemoIV
Description: A sterile, single use device. It is a non-patient stick blood collection device that attaches to a peripheral IV catheter (PIV catheter) and allows for blood sample collection to occur during continuous IV infusion therapy. The control blood sampling will occur via standard of care blood draws either through peripheral IV catheter or standard venipuncture.
Study: NCT05569291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Coaching Program (ACP)
Description: A semiautomated tele coaching program (application installed on a smartphone device with real time feedback and motivational messages) and a step counter (Fitbit Charge 4) providing direct feedback on total daily number of steps, walking time, time in at least moderate PA and movement intensity during walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Coaching Program (MCP)
Description: A telecoaching program using a step counter (Fitbit Charge 4) without this custom smartphone application but with the Fitbit application. This intervention will be more focused on weekly personal feedback from a coach by telephone.
Study: NCT05329961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil9
Description: The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
Study: NCT05402137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight stigma intervention
Description: Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
Study: NCT06297122

Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file (electronic health record). The identification of eligible cases will be conducted through an examination of the hospital's electronic microbiology database. Subsequently, the complete hospital record(s) of each patient will be used to extract a pre-defined set of variables required for data analysis.
Study: NCT05133440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radium dichloride
Description: Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium dichloride
Description: Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
Study: NCT06627673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Primary Total Knee Arthroplasty with a PEEK femoral component
Study: NCT05746104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Indocyanine Green (ICG) and Visualization of Tumor
Description: A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
Study: NCT06350747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: A laughter yoga session lasts approximately 30 minutes and consists of four parts. These parts are hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. The sections of laughter yoga are explained below (Kataria, 2011). Each laughter yoga session includes the same first three parts, with variations in the laughter exercises in the fourth part. In each new group, the first session will introduce participants to laughter yoga, its purpose, and objectives. Ten minutes are allocated for this section in the first session of each group. Therefore, the first sessions are 40 minutes long in each group, while all subsequent sessions are 30 minutes long. The total duration of the session, broken down by section, is as follows: Section 1: Hand Clapping and Warm-up Exercises - 5 minutes Section 2: Deep Breathing Exercises - 10 minutes Section 3: Playful Games - 5 minutes Section 4: Laughter Exercises - 10 minutes
Study: NCT05201469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VIB4920
Description: Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
Study: NCT06020638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
Study: NCT05822414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
Study: NCT04897256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TURN-IT exercise program
Description: Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.
Study: NCT06117579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Description of a typical session:~Session duration: between 12 and 20 minutes 3 cycles of 30 repetitions with 1 minute of break between each cycle. The patient should inhale as hard as possible against an inspiratory resistance generated by a valve device.
Study: NCT05517421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT06035224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
Description: AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
Study: NCT03494127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of GEL BALL FITTED MODULAR CUSHION
Description: DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of GEL BALL FITTED MODULAR CUSHION
Description: DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of SQUISHINS FITTED MODULAR CUSHION
Description: DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of SQUISHINS FITTED MODULAR CUSHION
Description: DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
Study: NCT06561516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Red ginseng)
Description: Step 1. Confrim the inclusion and exclusion criteria to select participants and abtain informed consent before surgery.~Step 2. Before surgery, research nurses randomly assign patients to either the Red ginseng or Control group (single-blind study).~Step 3. Blood tests and stool samples following rectal enema are collected from all patients before surgery.~Step 4. Depending on the type of gastrointestinal cancer (stomach cancer, pancreatobiliary cancer, colorectal cancer), radical resection surgery is performed.~Step 5. From 1 to 4 months after surgery, a three months period is designated for the Red ginseng group to take red ginseng tablets as instructed, with compliance assessements included.~Step 6. Four months after surgery, blood tests and stool samples are collected from all patients.~Step 7. After obtaining samples from the final registered patients, we will commission a contracted institution to conduct microbiome analysis test.
Study: NCT06561659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Condition
Description: Already described in the arm description

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Control Condition
Description: Already described in the arm description
Study: NCT02226432

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: - Postoperative Antagonistic Peripheral Magnetic Stimulation
Description: Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: - Postoperative Antagonistic Peripheral Magnetic Stimulation
Description: Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: - Postoperative Antagonistic Peripheral Magnetic Stimulation
Description: Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Peripheral Magnetic Stimulation
Description: Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesics
Description: Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesics
Description: Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesics
Description: Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
Study: NCT06254014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-4 Fc fusion protein injection
Description: 1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-4 Fc fusion protein injection
Description: The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
Study: NCT06366048

Intervention type: DIAGNOSTIC_TEST
Intervention: the different definitions of PHLF according to 50-50 criteria and ISGLS criteria
Description: Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.
Study: NCT04757584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blockers
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blockers
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.
Study: NCT06088628

Intervention type: DIAGNOSTIC_TEST
Intervention: Facial expression; Electroencephalogram; MRI
Description: Recording facial expressions of participants, EEG recordings, and MRI scans.

Intervention type: DIAGNOSTIC_TEST
Intervention: Facial expression; Electroencephalogram; MRI
Description: Recording facial expressions of participants, EEG recordings, and MRI scans.
Study: NCT05170737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.
Study: NCT04862416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R0.6C transmission blocking vaccine
Description: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
Study: NCT05999253

Intervention type: PROCEDURE
Intervention: Modified thoracolumbar plane block (mTLIP)
Description: Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia.

Intervention type: PROCEDURE
Intervention: Erector spinae plane block (ESP)
Description: Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia